UAE Radiotherapy Market Overview, 2031

Key Insights

• The UAE radiotherapy market operates within a rapidly evolving healthcare system, with significant government investment in advanced cancer care infrastructure. Cancer incidence in the UAE is rising, with global data indicating an increasing number of cancer diagnoses, particularly among younger patients, driving sustained demand for radiation oncology services.
• External Beam Radiotherapy (EBRT) constitutes the largest therapy segment, supported by an installed base of linear accelerators across public and private facilities. Advanced particle therapy is emerging as a significant market segment, with the UAE positioned to become a regional leader in this technology.
• Radiotherapy systems and equipment represent the largest offering segment, with the market characterised by substantial investment in next-generation technologies. IBA has signed a contract with YAS Healthcare to install a Proteus®ONE compact proton therapy system in Dubai, with an end-user price ranging between EUR 35 million and EUR 45 million including a multi-year maintenance contract. This will be the first operational proton therapy centre in the Gulf Cooperation Council region.
• Hospitals and integrated cancer centres are the largest end-user segment, with major healthcare providers including Cleveland Clinic Abu Dhabi and YAS Healthcare leading technology adoption. Cleveland Clinic Abu Dhabi has appointed HDP as Lead Designer and Supervision Consultant for the Middle East's first heavy-ion therapy facility, reinforcing Abu Dhabi's position as a global hub for healthcare innovation.
• Regulatory oversight is provided by the Dubai Health Authority, Ministry of Health and Prevention, and the Federal Authority for Nuclear Regulation. The Emirates Society of Radiation Oncology, established in 2024, represents a significant milestone in advancing radiation oncology through education, research, and clinical excellence standards across the UAE.

Market Outlook

• According to the research report, "UAE Radiotherapy Market Overview, 2031," published by Bonafide Research, the UAE Radiotherapy market is anticipated to grow at more than 9.20% CAGR from 2026 to 2031. This robust growth trajectory reflects significant government investment in healthcare infrastructure, rising cancer incidence, and the emergence of advanced particle therapy capabilities.
• The market is expected to benefit from substantial investment in advanced radiotherapy infrastructure. The Dubai Health Authority has granted initial approval to YAS Healthcare to establish the UAE's first proton therapy centre in Dubai, with construction slated to start in early 2026 and the facility expected to be operational by the end of 2028. The centre will provide patients across the region with access to proton therapy for the first time, eliminating the need to travel abroad for care.
• Advanced particle therapy capacity is expanding significantly. Cleveland Clinic Abu Dhabi has appointed HDP as Lead Designer and Supervision Consultant for the Middle East's first heavy-ion therapy facility, located in Abu Dhabi. With only a limited number of centres worldwide offering heavy-ion radiotherapy and no similar facilities within a five-hour flight radius of the UAE, this positions the UAE as a global hub for oncology innovation.
• The market is also influenced by professional standardisation efforts. The Emirates Society of Radiation Oncology was established in 2024 to advance education, research, and clinical excellence in radiation oncology across the UAE. ESRO will coordinate the development of consensus guidelines and recommendations to standardise radiotherapy practice across the country, working closely with health regulators to establish a national quality assurance framework.
• Long-term growth is supported by sustained government commitment. The proton therapy project aligns with the National Strategy for Wellbeing 2031, the Dubai Social Agenda 33, and the Dubai Economic Agenda D33 key initiatives to enhance quality of life and position Dubai as a premier destination for medical innovation.

Market Dynamics

Driver: Sustained Government Investment and Advanced Particle Therapy Expansion
The primary driver of the UAE radiotherapy market is sustained government investment in advanced cancer care infrastructure and the emergence of particle therapy capabilities. The Dubai Health Authority has granted initial approval to YAS Healthcare to establish the UAE's first proton therapy centre, a state-of-the-art facility expected to be completed by late 2028. This project is being developed in strategic collaboration with the National Cancer Centre Singapore, one of Asia's leading authorities in oncology, bringing global clinical and technical expertise to the design and implementation of the facility. IBA has signed a contract with YAS Healthcare for a Proteus®ONE compact proton therapy system, with a typical end-user price ranging between EUR 35 million and EUR 45 million including a multi-year maintenance contract. YAS Healthcare expects to begin treating patients in 2029, creating the first operational proton therapy centre in the GCC region. This sustained investment cycle ensures consistent demand for advanced equipment, installation services, and comprehensive maintenance contracts.

Challenge: Workforce Shortages and Infrastructure Constraints
A significant challenge facing the UAE radiotherapy market is the shortage of specialised personnel and the need for workforce development. Currently, there is no formal or accredited radiation oncology training in the UAE. All practicing radiation oncologists have obtained training and certification from abroad and, thereafter, obtained their licence to practice in the UAE. Specialised training for radiation oncology medical physicists and radiation therapists is currently not available in the UAE, with most licensed individuals having obtained their training certification abroad. The licensing health authorities have a rigorous process for verifying degrees and training, but the absence of local training pathways creates workforce constraints. Additionally, high initial setup costs for establishing radiotherapy facilities and the limited accessibility to advanced equipment in certain regions present ongoing challenges. The ESRO has identified addressing educational gaps, research fragmentation, and the lack of unified standards as critical priorities to help elevate radiation oncology to meet international benchmarks.



Trend: Professional Standardisation and Workforce Development
A major trend shaping the UAE radiotherapy market is the professionalisation of radiation oncology through the Emirates Society of Radiation Oncology and workforce development initiatives. ESRO, established in 2024, serves as a platform for the continuous medical education of radiation oncologists, medical physicists, dosimetrists, and radiation therapists. A top priority is to develop local training pathways, such as advocating for accredited residency and fellowship programmes in radiation oncology and establishing training programmes for allied professionals. Through mentorship and educational resources, ESRO aims to nurture the next generation of Emirati radiation oncology experts. The society also aims to foster collaborative research across the UAE's cancer centres, encouraging multicenter clinical trials, prospective registries, and data-sharing initiatives focused on radiotherapy outcomes. This trend toward professional standardisation and workforce development is expected to support the expansion of radiotherapy services and improve treatment quality across the UAE.

Policies

• The Dubai Health Authority grants initial approval for new radiotherapy facilities and provides regulatory oversight through its Health Regulation Sector. DHA licensed facilities providing oncology services must adhere to UAE laws and Dubai regulations, with specific requirements for radiation oncology services including radiotherapy services, mould rooms, and treatment planning rooms.
• Facilities must obtain a licence from the Federal Authority for Nuclear Regulation to use ionising radiology equipment. The FANR license is required before clinical operation can commence.
• The Ministry of Health and Prevention requires facilities to appoint a Medical Director or Physician-in-Charge, employ licensed healthcare professionals, and develop comprehensive policy and procedure documents including radiation safety policies, patient transfer plans, and medical emergency action plans.
• The Emirates Society of Radiation Oncology, established in 2024, coordinates the development of consensus guidelines and recommendations to standardise radiotherapy practice across the UAE. ESRO works closely with health regulators to establish a national quality assurance framework for radiation oncology.
• The Ministry of Health and Prevention's cancer control group is working to establish a UAE-level radiotherapy collaborative group, addressing the current lack of formal radiation oncology training in the UAE.
• DHA regulations require that oncology services shall only be provided in licensed health facilities including hospitals, day surgical centres, and cancer treatment centres. Facilities must ensure easy access, patient and staff safety, and appropriate equipment for managing critical and emergency cases.
• Federal Law No. 8 of 2019 on Medical Products and the Pharmacy Profession and Pharmaceutical Facilities provides the overarching legal framework for medical devices, including radiotherapy equipment, requiring marketing approval before commercialisation.

Segment Analysis

UAE Radiotherapy Market By Therapy Type
• External Beam Radiotherapy (EBRT): This is the largest therapy segment, supported by the installed base of linear accelerators across public and private facilities across the Emirates. IMRT and IGRT techniques are standard in major cancer centres. The segment is driven by the clinical dominance of EBRT for a broad spectrum of malignancies. Advanced particle therapy is emerging as a significant subsector: the YAS Healthcare proton therapy centre in Dubai, with a Proteus®ONE system, will begin treating patients in 2029, and the Cleveland Clinic Abu Dhabi heavy-ion facility will introduce carbon-ion therapy capabilities.
• Internal / Brachytherapy: This segment is clinically established, particularly for gynaecological and prostate cancers. Brachytherapy services are concentrated in specialised cancer centres with dedicated physics support. The regulatory framework under DHA and MOHAP requires specific provisions for radioactive source handling and disposal.
• Systemic Radiotherapy: This is the fastest-growing therapy segment, driven by the emergence of novel radiopharmaceuticals and targeted radionuclide therapies. The UAE's diverse patient demographics present unique opportunities for research in radiopharmaceuticals, with ESRO encouraging multicenter clinical trials and data-sharing initiatives.

UAE Radiotherapy Market By Offering
• Radiotherapy Systems/Equipment: This segment holds the largest market share by revenue, driven by high capital costs and significant public and private investment. Recent procurement demonstrates substantial capital expenditure: the YAS Healthcare contract with IBA for a Proteus®ONE system has an end-user price ranging between EUR 35 million and EUR 45 million including a multi-year maintenance contract. The Cleveland Clinic Abu Dhabi heavy-ion facility represents another multi-million dollar investment. Major equipment suppliers include Elekta, Varian Medical Systems, Accuray, and IBA (particle therapy). The UAE's goal to become a regional healthcare hub drives continued equipment investment.
• Software & Services: This is the fastest-growing segment, reflecting increasing digitalisation of radiation oncology. The software component includes advanced treatment planning systems and AI-powered tools ESRO has highlighted AI and machine learning as promising avenues to improve efficiency and standardise care. The services component encompasses installation, comprehensive maintenance, clinical training, and physics support. The YAS Healthcare contract includes a multi-year operations and maintenance agreement, demonstrating the importance of comprehensive service contracts for advanced systems.

UAE Radiotherapy Market By Application
• Breast Cancer: This is a major application segment, with breast cancer ranking among the most frequent malignancies in the UAE. Radiotherapy plays a central role in breast-conserving therapy and post-mastectomy treatment. The UAE's diverse population presents unique research opportunities for outcomes data specific to the region.
• Prostate Cancer: A significant application area, with proton therapy offering particular benefits for prostate cancer treatment due to reduced dose to surrounding organs. The YAS Healthcare centre will serve prostate cancer patients, and the Cleveland Clinic heavy-ion facility will offer carbon-ion therapy for prostate cancer and other malignancies.
• Lung Cancer: This segment is growing, with increased adoption of advanced radiotherapy techniques. Heavy-ion therapy offers particular advantages for lung cancer treatment, and the Cleveland Clinic facility will target lung cancer patients.
• Head & Neck Cancer: This is a critical application requiring highly conformal radiation delivery. Proton and heavy-ion therapies offer significant advantages in sparing adjacent critical structures.
• Central Nervous System / Brain: A significant application area, with proton therapy particularly beneficial for brain tumours and paediatric CNS tumours.
• Paediatric Cancers: Proton therapy is especially effective for paediatric cancers, as it reduces long-term side effects and protects healthy tissue during child development. The YAS Healthcare centre will serve paediatric patients, and the DHA has emphasised proton therapy's benefits for paediatric cancers.
• Other Applications: Includes gastrointestinal cancers, sarcomas, and recurrent cancers all targeted by the Cleveland Clinic heavy-ion facility.

UAE Radiotherapy Market By End User
• Hospitals & Integrated Cancer Centres: This is the largest end-user segment, with major healthcare providers leading technology adoption. YAS Healthcare is establishing the first proton therapy centre in Dubai, with construction beginning in early 2026 and operations expected by the end of 2028. Cleveland Clinic Abu Dhabi is developing the Middle East's first heavy-ion therapy facility. The National Cancer Centre Singapore serves as project consultant for the YAS Healthcare centre, bringing global clinical and technical expertise.
• Standalone Radiotherapy Centres: This segment includes specialised cancer treatment centres. The YAS Healthcare proton therapy centre will be a dedicated proton therapy facility, the first operational centre of its kind in the GCC. Independent centres are growing as the UAE expands its oncology infrastructure.
• Academic/Research Institutions: This is the fastest-growing segment, reflecting their central role in advancing the field through clinical trials and technology validation. ESRO aims to foster collaborative research across UAE cancer centres, encouraging multicenter clinical trials and prospective registries focused on radiotherapy outcomes. The National Cancer Centre Singapore's involvement brings research expertise to the region.
• Other Healthcare Facilities: Includes regional hospitals and community-based centres, contributing to broad-based demand for radiotherapy services as the UAE expands access across all Emirates.

UAE Radiotherapy Market Economics

• Equipment procurement in the UAE is conducted through both government and private investment. The YAS Healthcare contract with IBA for a Proteus®ONE system is valued at EUR 35 million to EUR 45 million including a multi-year maintenance agreement. The Cleveland Clinic heavy-ion facility represents a comparable capital investment.
• Service contract pricing reflects the critical clinical role of equipment uptime. The YAS Healthcare contract includes a multi-year operations and maintenance agreement, ensuring predictable maintenance costs and guaranteed availability for advanced proton therapy.
• The economic value of radiotherapy is well-recognised in the UAE. Proton therapy provides a treatment option with fewer side effects and lower toxicity for certain cancer types. The YAS Healthcare centre aims to improve accessibility and reduce costs by offering this treatment closer to home, eliminating the need for patients to travel abroad for care.
• High initial setup costs for advanced radiotherapy facilities present a financial barrier. The DHA has noted that the high costs associated with cutting-edge radiotherapy technologies are a key challenge facing the market.
• Workforce economics present challenges. The shortage of skilled radiation oncologists, medical physicists, and radiation therapists creates recruitment pressures. The UAE licensing health authorities have a rigorous process for verifying degrees and training, but the absence of local training pathways constrains workforce development.
• The cost of cybersecurity and software modernisation is an emerging factor, with ESRO highlighting AI and machine learning as promising avenues but requiring robust cybersecurity frameworks for connected devices.

Market Outlook by Infrastructure, Investment and Industry Development

• The YAS Healthcare proton therapy centre in Dubai represents the most significant investment in advanced radiotherapy in the UAE. The DHA has granted initial approval, with construction starting in early 2026 and operations expected by the end of 2028. The centre will create the first operational proton therapy centre in the GCC region, serving patients from across the Middle East.
• Cleveland Clinic Abu Dhabi has appointed HDP as Lead Designer and Supervision Consultant for the Middle East's first heavy-ion therapy facility. With just a limited number of centres worldwide offering heavy-ion radiotherapy and no similar facilities within a five-hour flight radius of the UAE, this positions the UAE at the forefront of global oncology care.
• The Emirates Society of Radiation Oncology, established in 2024, is advancing education, research, and clinical excellence in radiation oncology. ESRO is advocating for accredited residency and fellowship programmes in radiation oncology and establishing training programmes for allied professionals.
• The National Cancer Centre Singapore serves as project consultant for the YAS Healthcare proton therapy centre, bringing global clinical and technical expertise to the design and implementation of the facility. The centre will also incorporate AI and machine learning applications for treatment planning and quality assurance.
• Technology modernisation is advancing through the introduction of proton and heavy-ion therapies. The YAS Healthcare centre will feature IBA's Proteus®ONE system, upgradable over time to incorporate future technology advances. The Cleveland Clinic facility will include a CT-based image-guided system and multi-ion beam technology using carbon, helium, neon, and oxygen ions.
• Workforce development is a critical priority. Currently, there is no formal radiation oncology training in the UAE, with all practitioners trained abroad. ESRO's education initiatives and the development of local training pathways will be essential to building a sustainable workforce.
• The long-term outlook remains positive as cancer incidence continues to rise, and sustained government investment through the National Strategy for Wellbeing 2031 and Dubai Economic Agenda D33 drives equipment modernisation and infrastructure expansion across the UAE's healthcare system.



Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Radiotherapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• External Beam Radiotherapy (EBRT)
• Internal / Brachytherapy
• Systemic Radiotherapy

By Offering
• Radiotherapy Systems/Equipment
• Software & Services

By Application
• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Head & Neck Cancer
• Central Nervous System / Brain
• Gastro-intestinal
• Other Applications

By End User

• Hospitals & Integrated Cancer Centers
• Standalone Radiotherapy Centers
• Academic/Research Institutions
• Other Healthcare Facilities